Targeted therapy using alpha particles for neuroendocrine tumors
Official title: Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
Funded at University of Iowa · NIH-10850995 · Data updated 2026-11-12
This study is testing a new treatment for people with advanced neuroendocrine tumors that uses a special type of radiation to help shrink tumors more effectively than current options, and it aims to create a personalized approach based on imaging to ensure safety and effectiveness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | July 15, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $166,967 |
| NIH project number | 5R01CA243014-06 |
| Project ID | NIH-10850995 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced neuroendocrine tumors who have not responded adequately to existing therapies.
✕Less likely to help
Patients with early-stage neuroendocrine tumors or those who have not been diagnosed with this type of cancer may not benefit from this research.
What this research studies
This research focuses on developing a new treatment approach for patients with advanced neuroendocrine tumors using a targeted radionuclide therapy that employs alpha particles. The therapy aims to improve tumor regression and potentially achieve complete responses, which are rare with current treatments. The study will involve optimizing the production of a specific radiopharmaceutical and conducting preclinical trials to assess its safety and effectiveness. Patients may benefit from personalized therapy guided by imaging techniques that measure radiation dose accurately.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced neuroendocrine tumors, potentially leading to better outcomes and quality of life.
How similar studies have gone: There is emerging evidence suggesting that therapies using alpha-emitters have shown promise in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Menda, Yusuf — University of Iowa
- Study coordinator: Menda, Yusuf
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.